MyFinsight
Home
Compare
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
|
Compare
Income Overview
Revenue
$1,918K
Net Income
-$6,479K
Net Profit Margin
-337.80%
EPS
-$2.62
Unit: Thousand (K) dollars
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-06-30
Collaboration revenue
1,918
Research and development
8,823
General and administrative
2,490
Total operating expenses
11,313
Loss from operations
-9,395
Interest income and other income (expense), net
383
Interest expense
276
Change in fair value of convertible note
3,023
Net loss before provision for income taxes
-6,265
(provision for)/ benefit from income tax
212
Net loss
-6,477
Net unrealized loss on available-for-sale investments
-2
Net comprehensive loss
-6,479
Basic EPS
-2.62
Diluted EPS
-2.62
Basic Average Shares
2,475,898
Diluted Average Shares
2,475,898
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
Net comprehensive
loss
-$6,479K
Net loss
-$6,477K
Net unrealized loss
on...
-$2K
Net loss before
provision for income taxes
-$6,265K
(provision for)/ benefit
from income tax
$212K
Change in fair value of
convertible note
$3,023K
Interest income and other
income (expense), net
$383K
Loss from operations
-$9,395K
Collaboration revenue
$1,918K
Interest expense
$276K
Total operating
expenses
$11,313K
Research and development
$8,823K
General and
administrative
$2,490K
Buy us a coffee
Scribe Therapeutics, Inc. (SCTX)
Scribe Therapeutics, Inc. (SCTX)